Acrongenomics, Molecular Vision, and Pearson Matthews join forces to design a fully-manufacturable, prototype, point-of-care medical diagnostic device for detecting kidney and cardiac biomarkers
Design company Pearson Matthews has a reputation built around innovation and the development of breakthrough products.
This will be the first time that the Molecular Vision technology has been designed into a prototype commercial product.
The basis for the device will be the proprietary Molecular Vision technology which uses organic light emitters and photodetectors, coupled with microfluidics for the detection of biomarkers in bodily fluids.
The technology was first demonstrated to the public in March 2007.
The diagnosis relies on the optical characterisation of labelled biomarker molecules and can use fluorescence, absorption, chemiluminesence or any of the other usual optical detection methods.
Chris Wright, executive chairman of Molecular Vision, stated: "We are looking forward to working with Pearson Matthews and Acrongenomics on the development of our first commercial product.
"In combination, the three of us are able to provide innovative technology, product design and access to the market place."